For the quarter ended June 2025, Moderna (MRNA) reported revenue of $142 million, down 41.1% over the same period last year. EPS came in at -$2.13, compared to -$3.33 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $127.17 million, representing a surprise of +11.66%. The company delivered an EPS surprise of +28.76%, with the consensus EPS estimate being -$2.99.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product sales- United States: $88 million versus the three-analyst average estimate of $28.31 million. The reported number represents a year-over-year change of -45.7%.
- Product sales- Rest of world: $26 million compared to the $42.95 million average estimate based on two analysts. The reported number represents a change of +18.2% year over year.
- Revenue- Net Product sales: $114 million versus $81.42 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -38% change.
- Revenue- Other revenue: $28 million versus the six-analyst average estimate of $25.13 million. The reported number represents a year-over-year change of -50.9%.
- Revenue- Other revenue- Grant revenue: $5 million compared to the $6.16 million average estimate based on three analysts.
- Revenue- Other revenue- Licensing & royalty revenue: $2 million versus $10.65 million estimated by two analysts on average.
- Revenue- Other revenue- Collaboration revenue: $4 million versus the two-analyst average estimate of $7.5 million.
View all Key Company Metrics for Moderna here>>>
Shares of Moderna have returned -3.1% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
